Treatment of IBD patients with biologics (e.g., TNF antibody) that effectively control intestinal inflammation and induce remission in IBD patients, reduces risk of PD (despite most patients still having intestinal barrier dysfunction and microbiota dysbiosis) (91). Here, TNF is linked to Parkinson disease.